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Abstract
Background: The human immunodeficiency virus type 1 (HIV-1) Tat protein is a major viral
transactivator required for HIV-1 replication. In the nucleus Tat greatly stimulates the synthesis of
full-length transcripts from the HIV-1 promoter by causing efficient transcriptional elongation. Tat
induces elongation by directly interacting with the bulge of the transactivation response (TAR)
RNA, a hairpin-loop located at the 5'-end of all nascent viral transcripts, and by recruiting cellular
transcriptional co-activators. In the cytoplasm, Tat is thought to act as a translational activator of
HIV-1 mRNAs. Thus, Tat plays a central role in the regulation of HIV-1 gene expression both at
the level of mRNA and protein synthesis. The requirement of Tat in these processes poses an
essential question on how sufficient amounts of Tat can be made early on in HIV-1 infected cells to
sustain its own synthesis. To address this issue we studied translation of the Tat mRNA in vitro and
in human cells using recombinant monocistronic and dicistronic RNAs containing the 5'
untranslated region (5'-UTR) of Tat RNA.
Results: This study shows that the Tat mRNA can be efficiently translated both in vitro and in cells.
Furthermore, our data suggest that translation initiation from the Tat mRNA probably occurs by a
internal ribosome entry site (IRES) mechanism. Finally, we show that Tat protein can strongly
stimulate translation from its cognate mRNA in a TAR dependent fashion.
Conclusion: These results indicate that Tat mRNA translation is efficient and benefits from a
feedback stimulation by the Tat protein. This translational control mechanism would ensure that
minute amounts of Tat mRNA are sufficient to generate enough Tat protein required to stimulate
HIV-1 replication.
Background
The human immunodeficiency virus type 1 (HIV-1)
encodes for the three canonical polyprotein precursors
Gag, Pol, and Env, which are required for the formation of
infectious viral particles by infected cells. In addition,
HIV-1 encodes for six regulatory proteins, among which
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the Tat and the Rev factors are absolutely required for viral
gene expression at the transcriptional and post-transcrip-
tional levels in infected cells [1]. HIV-1 Tat is a small basic
protein that mainly localizes to the nucleus of infected
cells, where it acts as a potent transcriptional activator that
is indispensable for the synthesis of the full length viral
RNA (reviewed in [2-4]). Transcriptional activation by Tat
is mediated by multiple interactions between Tat and the
nascent viral TAR RNA and between Tat and cellular fac-
tors involved [5] in transcription initiation and elonga-
tion such as P-TEFb [4-11]. In addition, Tat has been
shown to stimulate translation of viral mRNAs [12-14].
Importantly, this cytoplasmic function of Tat seems to
require a nuclear experience, since the RNA-protein com-
plex formed between Tat protein and nuclear factors must
be assembled in the nucleus in order to later exert its func-
tion in the cytoplasm [12-14]. Thus, the HIV-1 Tat protein
plays a central role in the regulation of HIV-1 gene expres-
sion both at the level of transcription and protein synthe-
sis. The requirement of Tat in these processes poses an
essential question on how sufficient amounts of this viral
protein can be made early on in HIV-1 infected cells to
sustain its own synthesis. Soon after completion of viral
DNA synthesis by reverse transcriptase and before its inte-
gration into the host genome, the viral DNA can be tran-
scribed, but this generates only low levels of fully spliced
viral mRNAs encoding Tat and Nef [15]. These observa-
tions led us to hypothesize that Tat mRNA is translated
even under conditions where it is present in minute quan-
tities together with a high concentration of cellular
mRNAs.
Translation of mRNA into protein represents an essential
step in gene expression. The regulation of translation is a
mechanism used to modulate gene expression in a wide
range of biological situations including cell growth, devel-
opment and the response to biological cues or environ-
mental stresses such as viral infection [16-20]. During
viral infection at least two general modes of translational
control can be envisaged. The first represents a global con-
trol, in which the translation of most cellular mRNAs is
regulated. This is evident during the infection of some
members of the Picornaviridae [18-20] where global regu-
lation mainly occurs by the modification of translation
initiation factors. The second corresponds to a mRNA-spe-
cific control, whereby the translation of a particular
mRNA or a defined group of mRNAs is modulated with-
out affecting general protein biosynthesis or the transla-
tional status of the cellular transcriptome as a whole.
Translational control of a specific mRNA is normally
driven by regulatory protein complexes that recognize
particular elements that are usually present in the 5' and/
or 3' untranslated regions (UTRs) of the target mRNA [21-
24]. It is well recognized that translation control of pro-
tein synthesis is mostly exerted at the initiation step.
Translation initiation of eukaryotic mRNAs mostly occurs
by a scanning mechanism, whereby the 40S ribosomal
subunit binds to the mRNA 5' cap structure and scans the
RNA in the 5' to 3' direction until an initiation codon in a
favourable 'Kozak' context is encountered [25]. Transla-
tion initiation involves the recognition of the mRNA 5'
cap structure by eIF4F, which is composed of eIF4E, which
binds the 5' cap, eIF4A, and eIF4G, which links the mRNA
5' cap (via eIF4E)] and the 40S ribosomal subunit (via
eIF3) [26,27]. Studies on picornavirus protein synthesis
led to the discovery of an alternative mechanism of trans-
lation initiation, via an internal ribosome entry segment
(IRES) [28-30]. A major difference between cap-depend-
ent versus IRES-mediated ribosome binding and initiation
of translation is that the eIF4E component of the eIF4F
complex is dispensable for most of the latter activity
[31,32]. At present IRESes are defined solely by functional
criteria and cannot yet be predicted by the presence of
characteristic RNA sequences or structural motifs [30,33].
Despite these apparent experimental restraints, since the
initial characterization of IRESes in Picornaviridae, viruses
from other families including several members of the Ret-
roviridae  were found to initiate translation via an IRES
([34-41] reviewed in reference [42]). Indeed, internal
ribosome entry has been described in alpha- (ASLV), gam-
maretroviruses (MoMuLV) and lentiviruses (SIV and
HIV).
Based on these findings we wanted to study the mecha-
nism by which the Tat mRNA is translated using recom-
binant monocistronic and bicistronic RNAs containing all
or part of the 5' UTR of the Tat mRNA. In addition, we
examined the mechanism by which translation of the Tat
mRNA is controlled in vitro in rabbit reticulocyte lysates
(RRL) and in human cells. Our results show that the Tat
mRNA is efficiently translated in vitro and in cells, despite
the presence of large amounts of cellular mRNAs. Moreo-
ver, we show that the Tat protein exerts a positive feedback
on the translation of its cognate mRNA. Thus, Tat mRNA
appears to be efficiently translated even under conditions
where it is in minute amounts among highly abundant
cellular mRNAs. Taken together our data explains how
minute amounts of Tat mRNA can account for viral pro-
tein production required to kick-start HIV-1 replication.
Results
Molecular cloning of the Tat mRNA sequences
To study the mechanism of protein synthesis from the Tat
mRNA, we cloned the Tat1 and Tat2 sequences, the two
major forms of Tat mRNA [43], by means of a PCR-DNA
reconstruction protocol (Fig. 1 and Additional file 1).
Sequence analysis confirmed that by this strategy (see
methods and Fig. 1, panel B; Additional file 1), we were
able to fully reconstitute the Tat1 and Tat2 mRNA
sequences. Also, we constructed recombinant clonesRetrovirology 2009, 6:74 http://www.retrovirology.com/content/6/1/74
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where the Tat1 and Tat2 RNA sequences were inserted
next to the Renilla luciferase gene in either a monocis-
tronic or bicistronic vector (Fig 2, 3). To study translation
of the Tat RNA, we compared its level of translation with
that of a canonical efficiently translated mRNA, namely
the globin mRNA, in nuclease treated rabbit reticulocyte
lysate (RRL) or untreated RRL (URRL) in vitro [44]. In
addition, we investigated Tat mRNA translation in HeLa
cells, and the impact of the Tat protein on translation of
its cognate RNA.
Tat RNA versus globin RNA translation in vitro
Soon after its completion the viral DNA can be transcribed
by the host cell machinery, but this generates only low lev-
els of fully spliced viral RNAs in the absence of Tat and Rev
proteins [15]. To evaluate the efficiency of Tat mRNA
translation, we examined the relative translation levels in
the RRL of Tat1 and Tat2 RNAs expressing Renilla luci-
ferase (Rluc), in the presence of an excess of Glob-Fluc
RNA (Fig. 2), a 5' capped RNA that harbors the 5' UTR of
globin mRNA and drives expression of Firefly luciferase
(Fluc). Results revealed that the two Tat mRNAs were effi-
ciently translated even in the presence of a high concentra-
tion of Glob-Fluc RNA (data not shown). These
observations showed that even under unfavorable condi-
tions the Tat mRNA can be efficiently translated. These
results prompted us to further characterize the ability of
Tat mRNAs to be translated, despite being at a low con-
centration within a mixture of mRNAs.
The efficiency of Tat RNA translation was studied in the
non-nuclease treated RRL (URRL) [44], because it con-
Reconstitution of the complete Tat RNA sequences Figure 1
Reconstitution of the complete Tat RNA sequences. A. Organization of the splicing donor and acceptor sites in the 
HIV-1 pNL4.3 genome. B. Reconstitution of the complete Tat1 and Tat2 DNA sequences by PCR. "Hybridization PCR" can 
associate two different exons. Each Tat1 and Tat2 exon located in the pNL4.3 plasmid sequence (top panel) was independently 
amplified with specific oligonucleotides (Table 1). In fact, the antisense oligonucleotides used for exon amplification were 
designed in such a way that their 5' extremity is complementary to the 5' extremity of the next exon sense strand (see the col-
our codes). With this first PCR, the exon1 sense strand partially hybridizes with the exon2 antisense strand and the exon1 
antisense strand with the exon2 sense strand. Then "Amplification PCR" resulted in the accumulation of DNA corresponding 
to exon1 + exon2. All further steps needed to completely reconstitute the Tat1 and Tat2 sequences were performed using 
this procedure (Additional file 1). The only difference between Tat1 and Tat2 sequences corresponds to exon EX' (see bottom 
lane).
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B. Strategy by PCR DNA amplification of Tat sequences:
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tains a high concentration of endogenous globin mRNA
(about 7 × 10-7 M). We examined translation of Tat1 and
Tat2 RNAs expressing Rluc in the URRL (Fig. 2A) using
conditions where the 5' cap Glob-Fluc was also present in
excess (Fig. 2B; grey bars). Results show that under these
stringently competitive conditions Tat1 RNA and Tat2
RNA at a concentration of 1 × 10-9 M were translated (Fig.
2B, white and black bars, respectively) and levels of Tat
RNA translation linearly increased with increasing RNA
concentrations (see white and black bars).
Taken together, these results show that the two HIV-1 Tat
RNAs were efficiently translated in the URRL under condi-
tions where both the endogenous globin mRNA and the
recombinant Glob Fluc RNA were in vast excess. These
findings also show that even at low concentrations the Tat
mRNA can efficiently recruit ribosomes for its own trans-
lation.
Investigating Tat RNA translation in the rabbit reticulocyte 
lysate
The full-length mRNA from gammaretroviruses and lenti-
viruses can initiate protein synthesis by a cap-independ-
ent mechanism ([34,36-40]; reviewed in [42]). In most
instances IRESes in retroviruses and retroelements are
found within the 5'untranslated region (5'UTR) of the full
length mRNA. Furthermore, a report from Brasey et al.
[40] suggests that the Tat mRNA would exhibit IRES activ-
ity. In order to explore this possibility, translation initia-
tion of the Tat mRNA was studied in the RRL using both
monocistronic and bicistronic RNAs. As experimental
controls, we used canonical monocistronic and bicis-
tronic RNAs, the translation of which is exclusively 5' cap-
dependent (5' UTR of the globin RNA) or cap-independ-
ent (5' UTR of EMCV) (Fig. 3A and 3C).
Translation of Tat1 and Tat2 RNAs in the untreated RRL system Figure 2
Translation of Tat1 and Tat2 RNAs in the untreated RRL system. The top three lanes depict the Glob-Fluc, 
UTRTat1-Rluc and UTRTat2-Rluc RNAs used in the translation assays in the untreated RRL (URRL). The vertical bar in the 
5'UTR of Tat2 represents exon EX' (See fig. 1). Tat1 and Tat2 RNAs were translated in the URRL in the presence of a large 
excess of endogenous globin mRNA and of in vitro generated Glob-Fluc RNA. Independent experiments showed that 50 ng of 
Glob-Fluc RNA were saturating the URRL. Therefore 50 ng of Glob-Fluc RNA (grey bars) were used per assay together with 
increasing amounts of UTRTat1-Rluc (white bars) or UTRTat2-Rluc RNA (black bars). Note that under these stringent compe-
tition conditions, namely an excess of endogenous globin mRNA as well as Glob-Fluc RNA, UTRTat1/2 RNA at 5 ng (1 × 10-9 
M) were well translated (white and black bars, respectively).
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Results reported in figure 3B show that translation in the
RRL of the mono 5'Glob-RNA was 5' cap-dependent (see
β-galactosidase levels in lanes 2 and 3), while that of the
mono EMCV RNA was not (compare lanes 5 and 6). In
agreement with this, β-galactosidase was synthesized in
the context of the bicistronic Bi-EMCV RNA (lane 7) but
clearly not synthesized when the Bi-Glob RNA was used as
template (see B-Gal in lane 4). Results showed that for the
The Tat RNAs the mono-Tat1 and mono-Tat2 RNAs (Fig
3C) were translated in RRL (Fig. 3D). Strikingly, in the
monocistronic context, Tat1 and Tat2 RNA translation
occurred independently from the 5' cap structure (Fig. 3D,
compare lanes 1–2 and 4–5, respectively). In agreement
with this observation, the two cistrons of the Bi-Tat RNAs
were clearly expressed in the RRL (see Renilla and Tat in
lanes 3 and 6) albeit Tat was synthesized about 2.5 fold
less as compared with the monocistronic RNA (compare
lanes 2–3 and 5–6 in Fig. 3D). Thus, data show that Tat
can be synthesized in a cap-independent manner (Fig. 3C,
lanes 1–2) and as the 3' cistron of a bicistronic mRNA
(lane 3) while the globin 5' UTR was unable to direct β-
galactosidase synthesis under the same experimental con-
ditions (Fig. 3B, lane 4).
To further investigate Tat RNA translation in the RRL, the
monocistronic RNAs encoding the Tat protein were trans-
lated in the presence of the 7methyl-GTP cap analog (Fig.
3E, bottom panel). The rational of this experiment relies
on the competitive binding of initiation factor eIF4E to
the m7Gppp cap analog, which has been added in excess
to the in vitro reaction. Figure 3E (top panel, lane 2 and 3)
recapitulates results presented in Figure 3B (lanes 2 and 3)
where translation of the mono-Glob RNA is cap depend-
ent. As expected, the 7m-GTP cap analog reduced by 7
fold the translation of the capped mono-Glob RNA in the
RRL (lanes 2 and 3 in top and bottom panels) and had
only a marginal effect on the uncapped mono-Glob RNA.
The 7m-GTP cap analog did not affect translation from
the mono-EMCV RNA (compare lanes 4–5, in top and
bottom panels). In agreement with previous data (Fig.
3D), translation of the mono-Tat RNAs was not altered by
the addition of the 7m-GTP cap analog (Fig. 3E, top and
bottom panel, lanes 6–9).
Taken together, these results show that in the RRL the
HIV-1 Tat mRNA can be translated by an IRES mecha-
nism.
Tat mRNA translation in human HeLa P4 cells
To examine Tat mRNA translation in cells, we selected the
human HeLa P4 cells because this cell line is known to
support HIV-1 replication and is a convenient indicator
system to monitor HIV-1 Tat-mediated transactivation of
the viral LTR. In HeLa P4 cells the expression of the LacZ
gene is under the control of the LTR. Therefore, Tat expres-
sion will trans-activate the viral LTR and turn on produc-
tion of β-galactosidase (see methods). In this
experimental setting, the expression of the β-galactosidase
reporter is used as an indicator of Tat protein production.
In a first series of DNA transfection assays, it was found
that β-galactosidase was efficiently expressed upon trans-
fection of the full length Tat1 and Tat2 DNAs (data not
shown).
Next, we constructed bicistronic vectors containing the
Renilla luciferase (Rluc) as the cap-dependent 5' cistron
and the full length Tat1 or Tat2 sequences as the 3' one
(Fig. 4A, pdualTat1 and pdualTat2, respectively). In addi-
tion, we constructed a deletion mutant where the Tat 5'
UTR was removed; thus this construct contained only the
Tat coding sequence with the Tat initiation codon and 12
upstream nucleotides (Fig. 4A, pdualTatcod). In addition
a stable stem-loop (SSL) structure was inserted between
the two cistrons in order to prevent translating ribosomes
from reading through the intercistronic region, thus driv-
ing protein synthesis of the second cistron by a termina-
tion-reinitiation mechanism [40,45].
Results show that Rluc was expressed in a dose-dependent
manner upon transfection of the three recombinant pdual
DNAs (Fig. 4C). It is noteworthy that β-galactosidase was
expressed at a high level following pdualTat1 and
pdualTat2 transfection but was about 5–6 times less with
pdualTatcod, the construct lacking the Tat 5'UTR (Fig.
4B). In these experiments, Tat expression from the pdual-
Tatcod vector was considered as background due to the
leakiness of the experimental system. These ex vivo data
support our previous findings indicating that the Tat
mRNA can be translated in the context of a bicistronic
mRNA by a cap-independent mechanism.
To map sequences essential for Tat RNA translation in
such a bicistronic context, we examined the translation of
Tat1 and Tat2 recombinant RNAs in which the TAR-polyA
(pos. 1–104) and the TAR to the DIS (pos. 1–274)
sequences were deleted [see mutants pdual 2(Tat) and
pdual 3(Tat) in Fig. 5A]. Results reported in figure 5C
show that all vectors expressed Rluc to similar levels.
Monitoring Tat production through β-galactosidase activ-
ity (Fig. 5B) shows that deletion of the TAR-polyA stem-
loops had little influence on Tat expression in HeLa P4
cells, while further deleting the PBS-DIS sequences
decreased by 4–5 fold the expression of Tat as evaluated
by the level of β-galactosidase activity. As already noted,
the expression of the Tat protein from pdualTatcod, which
is the negative control, was extremely low (Fig. 5B).
These results indicate that in such a bicistronic context the
5' UTR sequences from the PBS to the Tat initiation codon
are necessary for Tat protein synthesis. Taken together, theRetrovirology 2009, 6:74 http://www.retrovirology.com/content/6/1/74
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Translation of the Tat RNA in the RRL system Figure 3
Translation of the Tat RNA in the RRL system. A. Structure of the recombinant Glob- and EMCV RNA templates. All 
recombinant RNAs encode LacZ as the sole gene for the monocistronic RNAs, and as the 3' one for the bicistronic RNAs. The 
5' UTR sequences correspond to either the complete 5' leader of the globin mRNA or the EMCV leader (see materials and 
methods). B. Translation of the mono- and bicistronic RNAs in the RRL system. RNAs were 5' capped (+) or not (-). Note that 
the non-capped mono-Glob RNA was translated at 15% (lane 3) of the control level (lane 2) while the non-capped mono-
EMCV RNA was translated at 125% (lane 6) of the control level (lane 5). LacZ was not translated with the Bi-Glob RNA (lane 
4) while it was at 90% (lane 7) the control level with the Bi-EMCV RNA. C. Structure of the recombinant Tat RNAs. The 
monocistronic and bicistronic recombinant Tat RNAs are shown. D. Translation of the mono- and bicistronic Tat RNAs in the 
RRL system. Note that mono-Tat1 and mono-Tat2 were translated at the same level either capped (lanes 1 and 4) or non-
capped (lanes 2 and 5). Translation of the Tat ORF occurred with the Bi-Tat RNAs, but levels were about 40% (lanes 3 and 6) 
of the control levels (lanes 1 and 5). E. Translation of the Tat RNAs in the presence of the cap analog 7m-Gppp. Translation 
conditions were as in B (upper panel), but contained 7m-Gppp (lower panel) during the whole reaction (see methods). Trans-
lation of the mono-Glob RNA was extensively inhibited (lane 2) but this was not seen with mono-EMCV RNA (lanes 4 and 5), 
as expected. Note that translation of the Tat RNAs was not inhibited by the cap analog (compare lanes 6-9 in upper and lower 
panels).Retrovirology 2009, 6:74 http://www.retrovirology.com/content/6/1/74
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data presented in figures 3, 4, 5 strongly suggest that the
Tat mRNA can be translated via an IRES-dependent mech-
anism both in vitro and in cell culture [40].
Trans-activation of Tat RNA translation by Tat in HeLa P4 
cells
Translational control of specific mRNAs is normally
driven by regulatory protein complexes that recognize
particular elements that are usually present in the 5' and/
or 3' untranslated regions (UTRs) of the target mRNA [21-
24]. Because Tat binds with high affinity to the 5' TAR ele-
ment, we wondered whether such a specific interaction
would have an impact on the translation of the Tat
mRNAs. Along this line, the Tat-TAR interaction has been
described to have an impact on translation of the full
length HIV-1 mRNA [13].
To examine this possibility we generated a series of DNA
constructs where the Renilla luciferase coding sequence
(Rluc) was preceded by a minimal 5' UTR (pRenilla), by
the 5' UTR of Tat1 or Tat2 (p5'UTR-Tat Renilla), or by the
5' UTR of the HIV-1 genomic RNA (5' UTR g-Renilla). In
addition, we used constructs where the 5' UTR of Tat1 and
Tat2 was deleted from the R-U5 sequences (pos. 1–104)
(p5'UTR2-Tat Renilla) (Fig. 6A and Additional file 2). The
Tat expressing vector contained a minimal 5'UTR fol-
lowed by the Tat coding sequence (Fig. 6A). Since Tat can
strongly activate transcription from the LTR, all Rluc val-
ues were normalized to the same copy number of Rluc
RNA in HeLa P4 cells, using RT-qPCR (see methods).
Results from a first series of experiments revealed that Tat
was able to trans-activate the translation of the UTR-Tat
and UTRg-RNAs (Additional file 2B), but not that of pRe-
nilla (data not shown). In the next series of assays, we
transfected low quantities of the Tat expressing DNA
(from 2 to 20 ng) and monitored Rluc activities (Addi-
tional file 2B). Upon normalization to the same RNA copy
number as assessed by RT-qPCR (see methods), the results
showed that Tat was able to activate by 5–10 fold the
translation of the viral Tat RNA and genomic RNA 5' UTRs
(see figure 6B and Additional file 2A). This Tat-mediated
activation of translation occurred for very low quantities
of transfected Tat DNA (2 to 20 ng per 2.5 × 105 cells), and
this was clearly less efficient with higher amounts of Tat
DNA (40–200 ng per 2.5 × 105 cells) (Additional file 2B).
It should also be noted that the 5' UTR of the HIV-1
genomic mRNA was about 3–4 fold less efficient than the
Tat 5' UTR in promoting Rluc expression in HeLa cells,
with or without Tat (Fig. 6B, compare top and bottom
panels, first and last bars, respectively).
Interestingly, deletion of the TAR-polyA sequences
(p5'UTR2-Tat Renilla) had two effects, leading to a higher
level of Rluc translation and no influence of Tat (Fig. 6C)
as compared with the p5'UTR-Tat Rluc construct (com-
pare Fig. 6B and 6C). These observations confirm that the
HIV-1 5'UTR restricts HIV-1 mRNA translation and sug-
gest that the Tat-TAR interaction relieves the translational
repression imposed by the leader structure [13,46,47]. As
expected, Tat had no effect on the expression of Rluc using
the pRenilla construct (Fig. 6C, top panel).
Analysis of Tat-mediated activation of Tat RNA 
translation in the RRL
Several studies show that Tat protein requires other cellu-
lar factors to exert the translational activation of the full
length HIV-1 mRNA [12-14]. Studies in Xenopus laevis
oocytes show that the HIV-1 RNA-Tat protein complex
must be assembled in the nucleus in order to facilitate
translation in the cytoplasm [14]. In agreement with these
observations, the above findings show that Tat protein
exerts a translational control on viral mRNA translation
from the 5'UTR. Furthermore, data show that this phe-
nomenon occurs even when low quantities of the Tat plas-
mid are used (Fig. 6B). Since Tat has potent RNA binding
and chaperoning activities [48] and stimulates translation
from the viral mRNA, we sought to evaluate if the Tat-TAR
interaction was responsible for the activation of viral RNA
translation and to establish if translational control by Tat
required other cellular factors. This possibility was inves-
tigated in vitro in the RRL and URRL using a recombinant
version of the Tat (1–86) protein [48], under different
experimental conditions.
Firstly, Tat was added to the RRL or URRL followed by
either one of the viral RNA, namely UTR-Tat or UTRg-RNA
expressing Rluc. Under these conditions, Tat was found to
have no, or at best a modest, positive effect on viral RNA
translation in vitro (data not shown). Secondly, Tat was
mixed with the RNA in vitro, and then the mix was added
to the RRL/URRL translation mixture. Under these condi-
tions translation of RNA containing either the complete 5'
UTR of the Tat RNA or of the genomic RNA was decreased
up to 3–4 fold upon addition of Tat (Additional file 3). At
the same time, Tat only slightly decreased the translation
of the Rluc RNA and that of a 5' UTR-Tat RNA where the
TAR-polyA has been deleted (Additional file 3). Thirdly,
Tat synthesized in the RRL and the Tat/RRL mixture was
added to either one of the viral Rluc RNAs and to the con-
trol Rluc RNA. Under these conditions, increasing quanti-
ties of Tat/RRL were found to strongly inhibit Rluc
translation from the viral 5'UTR and only slightly inhibit
that of the control Rluc RNA (data not shown).
Taken together these results show that the recombinant
Tat protein was not capable of exerting a positive effect on
the translation of its cognate mRNA. Furthermore, data
suggest that the Tat-TAR interaction inhibited protein syn-
thesis. We therefore reasoned that Tat-mediated transla-
tional activation of the HIV-1 RNA might require post-
translational modifications [49] and/or cellular cofactorsRetrovirology 2009, 6:74 http://www.retrovirology.com/content/6/1/74
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that are absent from the rabbit reticulocyte lysate. To
examine this possibility, URLL was supplemented with
HeLa cell extracts. The rationale of using these extracts
relies on reports showing that HeLa cell extracts support
translation of the full length HIV-1 RNA [40] and that
supplementation of RRL with cytoplasmic HeLa extracts
allowed efficient translation from the HIV-1 genomic 5'
UTR [40,50,51]. The addition of increasing amounts of
HeLa cell extracts, up to 0.2 μg/μl, to the URRL prior to
RNA translation did not modify the pattern of Rluc trans-
lation using the viral RNAs or the control RNA. Addition
of recombinant Tat (see materials and methods) to the
cell extract before translation had a slightly inhibitory
effect on viral and control Rluc RNA translation (data not
shown).
Finally, Tat was transiently expressed to a high level in
HeLa cells as assessed by western blotting (see methods
and data not shown), and these cells were used to prepare
a Tat-HeLa cell extract (see methods). Addition of increas-
ing amounts of the Tat-HeLa extract to the in vitro URRL,
prior to translation, caused a two fold increase in the level
Expression of Tat in HeLa P4 cells Figure 4
Expression of Tat in HeLa P4 cells. A. Top panel depicts the DNA constructs used in the experiments (at least three inde-
pendent assays were performed). SSL stands for a stable stem-loop to prevent ribosomes translating the Renilla cistron from 
reading through the Tat coding sequence. The pdualTatcod lacks the 5' UTR of the Tat RNA, except for the 12 nucleotides 
upstream from the Tat AUG codon (see materials). B. Middle panel shows the activity of newly made Tat, which activates LacZ 
transcription from the HIV-1 LTR in HeLa P4 cells. This was monitored by the β-galactosidase activity (see methods). C. Lower 
panel reports the Renilla luciferase activity (5' cistron) for each DNA construct. All values are expressed per μg of total pro-
teins. Integrity of all viral RNA expressed in HeLa P4 cells was assessed by Northern blotting (data not shown).
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of viral mRNA translation (Fig. 7A), while it had little or
no effect on the translation of the control Rluc RNA, or
viral RNA deleted from the TAR and polyA structures (Fig.
7B). To further study this Tat-mediated activation of trans-
lation in vitro, we used a recombinant Rluc RNA where the
5' leader corresponded to the viral 5' TAR-polyA stem-
loops. Translation of this recombinant RNA was
increased, up to 3 fold, by the Tat-HeLa cell extract (Fig.
7C).
Taken together these results favor the notion that Tat
requires post-translational modifications to be fully active
as a translational activator of its own mRNA. Alterna-
tively, Tat needs to interact with cellular factors, most
probably in the nucleus, in order to be able to activate
translation of the HIV-1 Tat and full-length RNAs in the
cytoplasm [12-14]. This last possibility stems from the fact
that HeLa cell extracts were incapable of assisting Tat-asso-
ciated translational activation when directly mixed with
the viral protein.
Discussion
In an attempt to understand how the viral transcriptional
factor Tat is initially synthesized for the sustained expres-
Expression of 5' UTR mutants of Tat RNA in HeLa P4 cells Figure 5
Expression of 5' UTR mutants of Tat RNA in HeLa P4 cells. A. Top panel depicts the DNA constructs used in the 
experiments. Deletions in the 5' UTR of Tat RNA are indicated. B. Middle panel shows the activity of newly made Tat that acti-
vates LacZ transcription from the HIV-1 LTR in HeLa P4 cells. This was monitored by the β-galactosidase activity (see meth-
ods) (at least three independent assays were performed). Note that deletion of either the entire 5' UTR (Tatcod) or the 
sequences encompassing TAR-pA-PBS-DIS strongly impaired Tat expression by the bicistronic RNA. C. Lower panel reports 
the Renilla luciferase activity (5' cistron) for each DNA construct. Integrity of the recombinant RNAs has been examined by 
Northern blotting. (not shown).
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Tat activates translation of its cognate mRNA Figure 6
Tat activates translation of its cognate mRNA. Panel A shows the monocistronic plasmids encoding Rluc used in these 
experiments. Panels in B report the results obtained with increasing amounts of pTat DNA, from 0 to 20 ng (at least 3 inde-
pendent assays were performed). In independent assays, optimal stimulation of Rluc expression was found to occur at 20 ng of 
pTat (Additional file 2). All results are reported as Rluc activity per RNA copy number monitored by RTqPCR (see methods). 
Note that the 5' UTR of Tat RNA is more active than that of the genomic RNA with or without pTat addition, in HeLa cells. 
Panels in C show that Tat did not influence expression of Rluc from plasmid pRenilla (top panel). In addition, the 5' TAR-pA 
sequences of the 5' UTR of Tat1 or Tat2 appear to be indispensable for Tat-mediated translational activation (lower panels).Retrovirology 2009, 6:74 http://www.retrovirology.com/content/6/1/74
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sion of the viral DNA in newly HIV-1 infected cells, we
investigated translation of the Tat mRNAs in vitro in rabbit
reticulocyte lysate systems (RRL and URRL) and in HeLa
cells. Our study focused on the two major forms of the Tat
mRNA, namely Tat1 and Tat2 (Fig. 1), because they repre-
sent about 80% of all Tat mRNAs in HIV-1 infected cells
[43]. Results showed that the HIV-1 Tat mRNA is effi-
ciently translated in vitro and in cells to the benefit of Tat
synthesis (Fig. 2, 3, 4, 5). The Tat mRNAs possess a 5' cap
and a 3' poly(A) tail together with a long 5' leader formed
of stable stem-loop structures (Fig. 8). Our data (Fig. 2, 3,
4, 5) indicate that like the full-length HIV-1 mRNA the Tat
mRNA can be actively translated by an IRES mechanism
[33-40], even when present in low concentrations (Fig. 2).
Interestingly, and in accordance with Tat protein function,
our data show that low quantities of Tat (Fig 4 and Addi-
tional file 2) can transactivate the HIV-1 promoter. The
ability of the Tat mRNA to be efficiently translated in com-
bination with the low amount of protein required to
transactivate the viral promoter would be essential during
the virus replication cycle as Tat protein is absolutely
required for the expression of the viral DNA in both its
unintegrated and integrated forms [1-3,15].
Tat mRNA translation appears to rely on an IRES mecha-
nism, in a manner similar to that found for the HIV-1 full-
length RNA [39,40]. This finding is not without precedent
since the Env mRNA of the gammaretrovirus MoMuLV
was shown to be translated by an IRES mechanism, in a
manner similar to that of the full-length RNA coding for
Gag and Gag-Pol [34]. In the case of the HIV-1 genomic
IRES, Brasey et al. [40] showed that the IRES overlaps the
primer binding site (PBS), the DIS, the splice donor (SD)
and the major Psi packaging signal that are located
upstream from the Gag initiation codon (Fig. 1 and 8).
Evidence was also provided showing that sequences
encompassing the PBS, the DIS and the SD had an IRES
activity (Figure four in [40]). In agreement with these
observations, we found that the TAR and polyA stem-
loops were not necessary for the IRES activity of the Tat
RNA (Fig. 5). Moreover, the Tat1 IRES activity was found
to be clearly more active than its genomic counterpart
(Fig. 6).
The above prompted us to look for a possible secondary
structure of the 5' UTR of the Tat RNA using a bioinfor-
matic approach (see methods) [52,53]. A putative consen-
sus secondary structure [54] is proposed in figure 8 where
the most conserved secondary structures in the 5' UTR of
Tat1 and Tat2 RNAs, which are not found in the 5' UTR of
the genomic RNA [[55] and ref. therein], are (i) an inter-
action between the PBS sequence and the 5' part of Tat
exon 2, (ii) a small non-structured segment rich in gua-
nine and adenine residues 5' to the Tat AUG codon, and
(iii) a small stem-loop next to the Tat AUG codon. In con-
trast, the TAR and polyA stem-loops remain as individual
structures present in the 5' UTR of both the Tat and
genomic RNAs, but are not required per se for the IRES
activity ([40], and Fig. 5). The single-stranded segments
present in the Tat 5' UTR could function as a landing pad
for the binding of ribosomes near or at the Tat initiator
codon (Fig. 8). This possibility is presently under investi-
gation. Moreover, the Tat IRES appears to actively recruit
the translation initiation complex to the benefit of Tat
synthesis, a process absolutely required for the sustained
expression of the viral DNA in the unintegrated or inte-
grated forms [1-3,15]. Cap-dependent translation is sup-
pressed during the G2/M phase of the cell cycle [56].
Interestingly, HIV-1 full length RNA synthesis is highly
stimulated during the viral induced G2/M arrest [57]. It is
tempting to speculate that this IRES activity ensures Tat
protein synthesis during the G2/M phase of the cell cycle
[40,58]. Synthesis of Tat during G2/M would be partially
responsible for the high degree of transcriptional activity
from the viral promoter observed during this phase of the
cell cycle.
Next we studied the influence of Tat on the translation of
its cognate mRNA. Results showed that Tat was able to
trans-activate the translation of Tat RNA, by up to tenfold
in HeLa cells (Fig. 6A, B), but not the translation of the
Rluc RNA (Fig. 6C, top panel). In addition, the 5' terminal
TAR-polyA sequences are required for the activation of Tat
RNA translation (Fig. 6C, lower panel). The Tat-mediated
activation of translation also most probably benefits the
other viral RNAs, notably the genomic RNA (Fig. 6B,
lower panel), which is in agreement with the finding of
Leibowitz [59]. We did not succeed in fully reconstituting
the translational activation of the viral RNAs by Tat in the
RRL systems (Fig. 7 and data not shown). A likely expla-
nation for these observations is that the recombinant Tat
protein used here conserves the RNA binding activity but
is incapable of recruiting cellular proteins required for the
Tat-mediated activation of translation. Results obtained
with HeLa and Tat-HeLa cell extracts are however in agree-
ment with what has been described in other experimental
systems [12-14] and favour the notion that Tat needs to be
post-translationally modifed or needs to contact cellular
factors in order to be able to activate translation from the
viral mRNA. An interesting possibility that also stems
from our findings is that Tat expression in cells might
transactivate cellular mRNAs coding for proteins required
for Tat to function as a translational activator of its cog-
nate mRNA. Tat is a basic protein with nucleic acid bind-
ing and chaperoning activities [48], and thus appears to
behave as a scaffolding protein for both viral transcription
and translation [1-11]. Yet, cellular factors recruited by Tat
for the translational activation of the viral RNA remain to
be determined [5], and this recruitment is presently under
investigation.Retrovirology 2009, 6:74 http://www.retrovirology.com/content/6/1/74
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Influence of Tat-HeLa cell extracts on Tat RNA translation in the RRL Figure 7
Influence of Tat-HeLa cell extracts on Tat RNA translation in the RRL. Tat-HeLa cell extracts were prepared as 
described in methods and increasing amounts added to the URRL. Results show that addition of increasing amounts of Tat-
HeLa cell extracts enhanced translation of the Tat and genomic UTR-Rluc RNA by up to two-fold (Panel A). On the contrary, 
there was no effect on the translation of Rluc RNA, or of 5' UTR-Rluc RNA lacking the TAR-pA sequences (panel B). In agree-
ment with this, translation of the TAR-pA-Rluc RNA was enhanced by up to three fold by the HeLa-Tat cell extracts (panel C). 
All experiments were carried out at least three times.
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Conclusion
This study shows that the Tat mRNA can be efficiently
translated under unfavourable conditions, suggesting that
only minute concentrations of mRNA are required to
assure the Tat protein concentration needed to stimulate
viral mRNA synthesis and translation. Moreover, we show
that the viral protein Tat exerts a translational control over
its cognate mRNA.
Methods
Cell culture
Human HeLa P4 cells, which express the CD4 receptor
and the bacterial LacZ gene under the control of the HIV-
1 LTR, were maintained in complete Dulbecco's Modified
Eagles's Medium with Glutamax (DMEM, Gibco, Life
Technologies Corporation, Carlsbad, California, USA),
supplemented with 10% FCS and penicillin and strepto-
mycin antibiotics.
Molecular Biology
Construction of the Tat DNA sequences
Because we experienced inaccurate RT-PCR amplification
of the Tat mRNAs extracted from infected cells, we
decided to construct the DNA fragments representing the
Tat1 and Tat2 mRNA sequences by PCR using the HIV-1
pNL4.3 DNA as a template. Specific DNA oligonucle-
otides (ODNs) (Table 1) used for the PCR reactions were
designed according to the Tat splice donor and acceptor
sites (D and A, respectively; see fig. 1). For Tat1, RNA splic-
ing removes two introns from D1 (pos. 743 on pNL4.3)
to A3 (pos. 5777) and from D4 to A7 (pos. 6044 to 8369).
Thus Tat1 RNA is formed of 3 exons in addition to the 5'
UTR, namely from pos. 454–743, pos. 5777–6044 and
pos. 8369–9528. Tat2 RNA is identical except for an addi-
tional very small exon, EX', pos. 4910–4962 (A1-D2; see
Fig. 1A).
Computer-assisted folding of the 5' UTR of Tat RNA Figure 8
Computer-assisted folding of the 5' UTR of Tat RNA. Folding of the 5' UTR of Tat1 RNA was carried out as indicated 
in methods. Small-case letters indicate that the folding of the given nucleotides was constrained in Mfold (see methods). 
Sequences and SL structures of importance are indicated, namely from 5' to 3' TAR, polyA (pA), PBS, the SD-SA border, and 
the Tat AUG (circled). Note that these SLs are present in the secondary structure of the genomic 5' UTR RNA ([39,40,52,55] 
and ref. therein). Note that the 29-nt long sequence upstream from the Tat initiator AUG is mostly unstructured and thus 
could serve as a landing pad for the ribosomes. ΔG's for the Tat UTR1 and UTR2, indicated on the right, reveal a high degree 
of stability (see methods and ref. [52]).
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The Tat DNA constructs also contain either the 5' LTR for
ex vivo expression, or the T7 RNA polymerase promoter for
in vitro RNA synthesis (see below). In addition, it was nec-
essary to omit the 3' R sequence to prevent frequent
recombination reactions during amplification.
The Tat exons were independently PCR amplified (Fig.
1B) using the designed ODNs (Table 1 and Additional file
1) and the Vent polymerase (New England Biolabs, Ips-
wich, MA, USA). Then, reconstitution of the Tat1 and Tat2
DNA fragments was carried out (Fig. 1B): minus strand
ODNs were designed in such a way that their 5' extremity
was complementary to the 5' extremity of the plus strand
of the next exon (Table 1). Thus, by means of a "hybridi-
zation PCR" procedure, each exon was linked to the next
one and the resulting DNA was subsequently amplified by
PCR using additional ODNs (Table 1).
Plasmid DNA construction
(i) Plasmid DNA with Tat sequences. The complete Tat1
and Tat2 DNA fragments (Fig. 1B) and the deleted Tat1
and Tat2 DNA fragments were cloned into pD2EGFP-N1
(Clontech Mountain View, CA, USA) at the EcoRI/NotI
sites, in place of the eGFP gene. The Tat DNA fragments in
pD2EGFP-N1 were recovered upon EcoRI/XbaI digestion
and cloned into the pdualuc bicistronic plasmid [39],
cleaved by EcoRI/XbaI.
The same Tat DNA fragments were also cloned into the
p0pRenilla vector at the XbaI restriction site, next to the
Renilla Luciferase gene.
The HIV-1 U3 promoter/enhancer region was PCR ampli-
fied as above using the HIV-1 pNL4.3 DNA template and
cloned into p0pRenilla at the PvuII site, generating the
pRenilla plasmid. We used this new DNA construct to
insert at the NcoI site, 5' to the Renilla gene, each one of
the DNA fragments corresponding to the complete 5' UTR
of Tat1 and Tat2 RNAs, to the deleted 5' UTR (delta R-U5)
of Tat1 and Tat2 RNAs, to the 5' UTR of the viral genomic
RNA, and to the 5' first 111 nt of Tat RNA.
The Tat1 and Tat2 DNA fragments were also cloned into
pRenilla at the NcoI/SmaI sites, in place of the Renilla
Luciferase gene.
(ii) Other plasmid DNA. Plasmids pAB300-UTRGlobin
and pAB300-UTREMCV contain the 5' UTR of the globin
and EMCV RNA, respectively, at the NheI site just before
the LacZ gene in pAB300.
Plasmids pBis-UTRGlobin and pBis-UTREMCV contain
the 5' UTR of the globin and EMCV RNA, respectively, at
the NheI site in the intercistronic region of the pBis plas-
mid [40].
DNA transfection
HeLaP4 cells were plated at 250 000 cells per well in six-
well plates in complete medium and DNA was transfected
using Lipofectamine and Plus reagent (Invitrogen Life
Technologies Corporation, Carlsbad, California, USA). 48
hours post transfection, HeLa P4 cells were lysed with 250
μl of lysis buffer per well and the Renilla Luciferase and β-
Galactosidase activities were monitored with the 'Renilla
Luciferase Assay system' (Promega Corporation, Madison,
WI, USA) and 'β-gal Reporter Gene Assay' (Roche Molec-
ular Systems, INC., Branchburg, NJ, USA), respectively. All
measurements were performed with a Promega luminom-
eter by substrate injection. All results were normalized for
the same amount of total proteins in the HeLa cell
extracts.
Reverse transcription and quantitative PCR reactions
RNA was extracted from cells using the Trizol reagent (Inv-
itrogen), according to the manufacturer's instructions.
Two μg of total cellular RNA were used per reverse tran-
scription reaction using the SuperScript II reverse tran-
scriptase (Invitrogen), and 1 μM of the given ODN
(Table 1).
The mixture was heated for 5 min at 65°C and then kept
on ice. Next it was incubated for 2 min at 42°C and RT
was added. The reaction was for 50 min at 42°C.
To quantitatively assess RNA levels by cDNA amplifica-
tion, we used the 'LighCycler FastStart DNA Master SYBR
Green kit (Roche).
In vitro RNA synthesis and translation
In vitro transcription
The DNA templates of interest were linearized, purified by
a phenol/chloroform extraction, and ethanol precipitated.
2 μg of DNAs were used per transcription reaction. In vitro
RNA synthesis was performed as previously described
[38,44] for 1 h 30 min at 37°C in 50 μl final volume. For
capped RNA synthesis, m7Gppp was added at the begin-
ning of the reaction at 1 mM final concentration.
RNA recovery
40 μl of LiCl (7.5 M, 75 mM EDTA) were added to the
transcription reaction, which was kept for 30 min at -
20°C. Then RNAs were recovered by centrifugation at
14000 g, 4°C for 30 min. The RNA pellets were washed
with 120 μl of 70% ethanol, dissolved in 30 μl of pure
water and kept at -20°C.
RNA translation in the rabbit reticulocyte lysate system
In vitro synthesized RNAs (5–100 ng) were translated in
10  μl of either 25% Flexi® Rabbit Reticulocyte System
(Promega, USA) or the supplemented untreated RRL 50%
(v/v) (as described in [44]) in the presence of 75 mM KCl,Retrovirology 2009, 6:74 http://www.retrovirology.com/content/6/1/74
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0.5 mM MgCl2, 20 μM of each amino acid (minus
cysteine) and 0.6 mCi/ml of [35S]-cystein (GE Healthcare
Life Sciences Piscataway, NJ, USA).
Tat protein added to the in vitro translation reactions was
chemically synthesized as described in [48] (CNRS,
Immunologie et Chimie Thérapeutiques, UPR 9021-
Strasbourg).
Reactions were at 30°C for 45 min and stopped by the
addition of 90 μl of buffer (0.1 mM DTT; 35% glycerol;
0.2 M Tris-HCl pH 6.8; 1% SDS; 0.5% bromophenol
blue). 10 μl were loaded onto a 15% polyacrylamide-SDS
gel (PAGE-SDS). After protein resolution, the gel was fixed
in a solution containing 30% methanol and 10% acetic
acid for 30 min, and subjected to autoradiography using
Biomax films (Eastman Kodak, USA). Densitometric anal-
yses were performed by Phospho Imaging with a Storm
850 phosphoimager. To evaluate the translation level of
RNA encoding Renilla Luciferase, we monitored the
Renilla luciferase activity directly from the translation
reaction. Reactions were stopped with 40 μl of lysis buffer
from the " Renilla Luciferase assay system" and 20 μl of
that mixture were used to quantify the Renilla luciferase
activity by luminometry.
Cytoplasmic extract of HeLa P4 cells
HeLa P4 cells (1 × 107) were washed with PBS, trypsinized
and transferred in a 15 ml tube, and then centrifuged at
1500 rpm at 4°C for 5 min. All subsequent steps were car-
ried out on ice. The cell pellet was washed twice with 10
ml of PBS, 2% FCS and centrifuged at 1500 rpm for 5 min.
Table 1: DNA oligonucleotides used in the present study
Oligo DNA Sequence and position on Tat mRNA
LeaderR sense EcoRI 5' GAATTCGGTCTCTCTGGTTAGACCAGATC 3'
(exon1 sense for Tat1 et Tat2: 1→)
Leader rev1 5' TATTCTGCTATGTCGACACCCAATTCAGTCGCCGCCCCTCG 3'
(exon1 reverse for Tat1:← 290)
Leader rev2 5' GGATCTCTGCTGTCCCTGCAGTCGCCGCCCCTCG 3'
(exon1 reverse for Tat2:← 290)
Ex2Tat sense 5' AATTGGGTGTCGACATAGCAGAATAGGCG 3'
(exon2 sense for Tat1:290→ and for Tat2:343→)
Ex2Tat rev 5'GGGATTGGGAGGTGGGTTGCTTTGATAGAGAAGCTTGATGAGTCTGACTG3' (exon2: reverse for Tat1:← 558 
and for Tat2:← 611)
Ex'Tat sense 5'CAGGGACAGCAGAGATCCAGTTTGGAAAGGACCAGCAAAGCTCCTCTGGAAAG 3' (exon':sense for Tat2:290→)
Ex'Tat rev 5' CTGCTATGTCGACACCCAATTCTTTCCAGAGGAGCTTTGCTG 3'
(exon':reverse for Tat2:← 343)
Ex3Tat sense 5' ACCCACCTCCCAATCCCGAG 3'
(exon3: sense for Tat1:558→ and for Tat2: 611→)
Tatrev NotI 5' TAATAATGCGGCCGCAGTACAGGCAAAAAGCAGCTGCTTATATGC 3'
(exon3: reverse for Tat1:← 1718 and for Tat2:← 1770)
PBSEcoRI sense 5' TATATTAGAATTCGTGTGCCCGTCTGTTGTGTGACT 3'
(exon1: sense for Tat1 and for Tat2:104 →)
SDEcoRI sense 5' ATATAAGAATTCCGAGGGGCGGCGACTG 3'
(exon1: sense for Tat1 and for Tat2:274→)
AUGEcoRI sense 5' TATAATAGAATTCATGGAGCCAGTAGATCCTAGACTAGAG 3'
(exon2: sense for Tat1:343 → and for Tat2:396 →)
TatNcoI sense 5' TAATATACCATGGGGTCTCTCTGGTTAGACCAGATC 3'
(exon1: sense for Tat1 and for Tat2:1→)
TatSmaI rev 5' TATATACCCGGGAGTACAGGCAAAAAGCAGCTGCTTATATGC 3'
(exon3: reverse for Tat1:← 1718 and for Tat2:← 1770)
TatXbaI sense 5' ATATATTCTAGAGGTCTCTCTGGTTAGACCAGATC 3'
(exon 1:for Tat1 et Tat2:1→)
TatXbaI rev 5' TAATAATTCTAGAAGTACAGGCAAAAAGCAGCTGCTTATATGC 3'
(exon3 reverse for Tat1:← 1718 and for Tat2:← 1770)
(111)NcoI rev 5' TATATACCATGGGGCACACACTACTTTGAGCACTCAAGG 3'
(exon1:reverse:← 111)
UTRTatNcoI rev 5' TATATTACCATGGTTCTTGCTCTCCTCTGTCGAGTAACG 3'
(exon2: reverse for Tat1:← 342 and for Tat2:← 395)
(1-336)NcoI rev 5' ATATATACCATGGCTCTCTCCTTCTAGCCTCCGC 3'
(reverse: 5' to AUG of the RNAg)
UTR2TatNcoI sense 5' TAATATACCATGGGTGTGCCCGTCTGTTGTGTGACT 3'
(exon1: sense for Tat1 and for Tat2:104 →)
LTRPvuII sense 5' TAATATACAGCTGTGGAAGGGCTAATTTGGTCCC 3' (sense for U3)
LTRPvuII rev 5' TATATTACAGCTGAGTACAGGCAAAAAGCAGCTGC 3' (reverse for U3)Retrovirology 2009, 6:74 http://www.retrovirology.com/content/6/1/74
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The cell pellet was resuspended in two volumes of hypot-
onic buffer (HEPES-KOH 10 mM, pH 7.6, potassium ace-
tate 10 mM, MgOAc 0.5 mM, DTT 1 mM, protease
inhibitors, and RNasin (40 U/ml)), and cells were lysed
by passing through a needle. The cellular lysate was cen-
trifuged at 14000 g for 10 min and the supernatant was
analysed for its total protein content and kept at -80°C.
Western blotting
Two methods have been used to directly assess Tat expres-
sion in HeLa P4 cells.
Firstly, a Hybond-P membrane (GE Healthcare) was acti-
vated by means of a methanol-air treatment and rinsed in
20% methanol, 25 mM Tris pH 8 and 192 mM Glycine.
Then, 0.5, 1, 2 and 5 μg of total or cytoplasmic extracts
from HeLa P4 cells expressing HIV-1 Tat were carefully
spotted onto the membrane. Next, the membrane was
incubated during 1 h at 20°C in TBS-T (Tris-HCl pH 8, 50
mM, NaCl 0.15 M, 0.5% Tween 20) containing 5% milk
powder, and then for 12–14 hours at 4°C in the presence
of the mouse monoclonal anti-Tat antibody (antiTat7S
directed againts the basic region of Tat) (a kind gift from
Michel Leonetti, the CEA, France). Then, the membrane
was extensively rinsed three times in TBS-T, and incubated
with an anti-mouse IgG antibody (Dako). The membrane
was rinsed three times in TBS-T, and incubated 5 min in
the presence of the peroxydase substrate (Supersignal
West Pico Chemiluminescent kit, Perbio).
Secondly, classical western blotting was carried out as
above except that the cellular extracts (15 μg) were run
over a 15% SDS PAGE gel. Detection of the chemolumi-
nescent signals was carried out by autoradiography, as
before.
Bioinformatics
A putative secondary structure for the 5' UTR of Tat1 and
Tat2 RNAs was determined by means of bioinformatic
analyses.
Firstly, 27 divergent sequences were selected in the HIV-1
genomic RNA database (Los Alamos database)
http:www.hiv.lanl.gov/content/sequence/HIV/main
page.html. Reconstitution of the complete Tat1 and Tat2
RNA sequences was carried out by manual splicing. Then,
the sequences were aligned with the ClustalW software
[53], and the alignments were manually edited. The
obtained alignments were used to establish a consensus
secondary structure for the Tat1 and Tat2 RNAs, using the
RNAalifold software of the Vienna RNA package [52]. Var-
iability in the aligned RNA sequences, with special
emphasis on co-variant sites, together with the consensus
structure, was used to infer putatively conserved second-
ary structures in Tat1 and Tat2 RNAs. Apart from the TAR
stem-loop, the most conserved structural features in the 5'
UTR of Tat RNAs are: (i) an interaction between the PBS
sequence and the 5' part of Tat1 exon 2 which is conserved
in all sequences of the Los Alamos database; (ii) a small,
non-structured segment rich in guanine and adenine 5' to
the Tat AUG codon; and (iii) a small stem-loop next to the
Tat AUG codon (Fig. 8). These features were used as con-
straints in Mfold [54] for the folding of the pNL4.3 Tat
RNA sequences.
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Supplementary Figure S3. Influence of Tat protein on RNA transla-
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materials and in figure 2. The Tat (1–86) protein was provided by S. 
Muller (CNRS, Strasbourg) and was bound to the relevant RNA template 
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TAR-pA sequences (panel B).
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